Hodgkin lymphoma (HL) is curable in most cases by modern chemotherapy with or without radiotherapy (CT ± RT). Most treatment failures represent either primary refractory disease or early relapses within 1 year (PR/ER). Relapses >1 year from treatment completion are considered “late relapses” (LR) associated with better outcomes [1]. The relapse rate gradually drops after the first year [2] and patients with sustained complete remission (CR) for >5 years are generally considered “cured”. However, relapses after >5 years (very late relapses [VLRs]) occasionally occur, and, until recently, VLRs after CT ± RT had been evaluated in rather small patient series [3–11]. In 2005, we initially analyzed the incidence of VLRs—those occurring >5 years from initial treatment initiation—and searched for relevant prognostic factors. In 2017, the German Hodgkin Study Group (GHSG) analyzed the incidence of VLRs in 4935 patients mainly treated with CT ± RT within the HD7-HD12 trials, reporting a linear pattern of continuous relapses up to 20 years [12]. However, it continues to be unclear if this linear trend continues beyond 20 years without reaching a plateau and if baseline prognostic factors or treatment regimens or RT strategies affect the risk of VLR.

We attempted to shed light on these questions by analyzing our cohort of 1143 patients in sustained CR >5 years after CT ± RT initiation, with >90% coming from a single center and treated mostly with ABVD or equivalent regimens (ABVDeq). The median follow-up was 13.8 years (IQR 9–20.7, range 5–47). The outcome of VLRs will be reported separately in a wider multicenter study [13].

Patients, treatment strategies and methods are described in detail in the Supplementary Material. The study flow-chart is shown in Supplementary Fig. 1. The primary endpoint was the cumulative incidence (CumInc) of VLR after the 60-month landmark from diagnosis considering the competing risk of death from any cause without prior relapse.

The baseline characteristics of the 1143 patients are shown in Supplementary Table 1. Among them 94% had cHL (nodular sclerosis (NS) 65%, mixed cellularity (MC) 24%), 91% received ABVDeq regimens and 73% received RT as combined modality treatment (CMT).

VLRs occurred in 66/1143 patients (2 as composite lymphoma). VLRs were initially compared to an additional group of 327 patients with PR/ER (n = 249) or LR 2–5 years (n = 78) (all defined from treatment initiation) (Supplementary Table 1). There was a monotonous drop of the frequencies of NS, ESR ≥ 50 mm/h (p < 0.001) and anemia (p = 0.008) from PR/ER to LR and VLR patients, while MC increased from 17 to 26% and 46% (p < 0.001). IPS was lower in VLRs compared to LR and PR/ER (p = 0.004); advanced-stage, B-symptoms, leukocytosis, lymphocytopenia and hypoalbuminemia were overrepresented in PR/ER but did not differ between LR and VLR.

Among VLRs the median time-to-relapse was 9.3 years (IQR: 6.1–15, range 5–35). The distribution and CumInc of VLRs are presented in Supplementary Table 2 and Fig. 1A. The CumInc of VLRs showed continuous upward trend over time without signs of levelling off. The CumInc of VLR at 20 and 30 years from diagnosis for the whole patient population was 7.9% and 12.2% respectively. After treatment with ABVDeq ± RT it was 7.2 and 12.7% (Supplementary Table 3), and 7.2 and 13.6% for the 978 cHL patients (Supplementary Table 4 and Fig. 1E, F).

Univariate and multivariate prognostic factor analysis is provided in Table 1. In univariate analysis of all patients, age ≥45 years and MC were associated with higher probability of VLRs, while ABVDeq vs. MOPP-type CT ± RT and CMT vs. CT alone were associated with lower VLR incidence (Table 1 and Supplementary Fig. 2 and Fig. 1C). Clinical stage and B-symptoms were of borderline significance (p = 0.11 and 0.13; Table 1); interestingly however, elevated ESR ≥ 50 mm/h was inversely associated with the incidence of VLR (Table 1 and Fig. 1D). Focusing on histology, MC was associated with higher VLR incidence compared to non-MC cHL, mainly driven by the favorable effect of NS, while NLP was marginally associated with more VLRs compared to non-MC cHL (Table 1 and Fig. 1B). In multivariate analysis (Table 1), independent protective factors for VLRs were CMT vs. CT (HR = 0.35, p < 0.001) and elevated ESR (≥ 50 vs. < 50 mm/h; HR = 0.46, p = 0.008), while MC was independent adverse factor (HR = 2.19, p = 0.004). If ESR (with associated missing values) was not considered, ABVDeq CT vs. MOPP-type was protective against VLRs (HR = 0.50, 95% CI 0.27–0.94, p = 0.032) in the presence of other significant predictors (CMT/CT and MC) (data not shown).

If the analysis was restricted to patients treated with anthracycline-based CT (n = 1042 including 50 VLRs), both MC (HR = 2.20, p = 0.015) and age ≥45 years (HR = 1.81, p = 0.082) entered the final backward model as independent adverse prognostic factors, while elevated ESR (≥ 50 vs. < 50 mm/h; HR = 0.49, p = 0.039) and CT ± RT vs. CT (HR = 0.53, p = 0.062) were selected as independent protective factors in multivariate analysis (Table 1).

In multivariate analysis focusing to patients with cHL treated with anthracycline-based CT (n = 978 including 46 VLRs), both MC (HR = 2.84, p = 0.001) and age ≥45 years (HR = 1.99, p = 0.031) were independent prognostic factors (Table 1). Finally, when the analysis was restricted to patients treated after 1996, the significance of MC was confirmed (HR = 2.91, p = 0.009) and use of RT was retained in the backward model as a protective factor (HR = 0.45, p = 0.058) (data not shown).
Fig. 1  Cumulative incidence of very late relapses and competing-risks-adjusted cumulative incidence at different time-points from diagnosis in the whole patient population and in individual patients’ subgroups. Individual graphs refer to the whole patient population overall (A) and according to histologic subtype (cHL classical Hodgkin lymphoma, MC mixed cellularity, NLPHL nodular lymphocyte-predominant Hodgkin lymphoma) (B), radiotherapy (RT) administration (C) and erythrocyte sedimentation rate (ESR) (D). In addition, cumulative incidence of very late relapses and competing-risks-adjusted cumulative incidence at different time-points from diagnosis in patients with classical Hodgkin lymphoma treated with ABVD or equivalent regimens (E, F) and according to histologic subtype (cHL classical Hodgkin lymphoma, MC mixed cellularity) (G), radiotherapy (RT) administration (H), erythrocyte sedimentation rate (ESR) (I) and age (J).
Table 1. Univariate and multivariate competing-risks regression analysis of prognostic factors for very late relapse in the whole patient series, in ABVD treated patients and in ABVD treated patients with classical Hodgkin lymphoma.

| Variable                          | All patients (N = 1143, 66 events) | ABVD-treated patients (N = 1042, 50 events) | ABVD-treated patients with cHL (N = 978, 46 events) |
|----------------------------------|-----------------------------------|---------------------------------------------|---------------------------------------------------|
|                                  | Univariate analysis               | Multivariate analysis                       | Univariate analysis                               | Multivariate analysis |
|                                  | sHR (95% CI)                      | p value<sup>a</sup>                         | sHR (95% CI)                                      | p value              |
| Age (≥45 vs. <45)                | 1.74 (1.04–2.90)                 | 0.034 DNE                                   | 2.34 (1.20–4.38)                                 | 0.01                 |
| Gender (male vs. female)         | 1.43 (0.87–2.35)                 | 0.155 DNE                                   | 1.44 (0.81–2.54)                                 | 0.211 DNE            |
| Stage (IB/IIB/III/IV vs. IA/IIA) | 1.49 (0.92–2.43)                 | 0.107 DNE                                   | 1.30 (0.74–2.30)                                 | 0.364 DNE            |
| Histology                        | 1.47 (0.90–2.41)                 | 0.127 NE                                    | 1.35 (0.76–2.42)                                 | 0.306 NE             |
| Gender (male vs. female)         | 1.43 (0.87–2.35)                 | 0.155 DNE                                   | 1.44 (0.81–2.54)                                 | 0.211 DNE            |
| Stage (IB/IIB/III/IV vs. IA/IIA) | 1.49 (0.92–2.43)                 | 0.107 DNE                                   | 1.30 (0.74–2.30)                                 | 0.364 DNE            |
| Histology                        | 1.47 (0.90–2.41)                 | 0.127 NE                                    | 1.35 (0.76–2.42)                                 | 0.306 NE             |
| Chemistry (MOPP vs. ABVD)        | 0.67 (0.28–1.59)                 | 0.359 NE                                    | 0.74 (0.45–1.24)                                 | 0.675 NE             |
| Radiotherapy (yes vs. no)        | 2.72 (1.64–4.52)                 | <0.001 DNE                                  | 0.78 (0.48–1.32)                                 | 0.458 NE             |
| Anemia (present vs. absent)      | 2.11 (0.89–5.47)                 | 0.087 NE                                    | 2.01 (0.87–4.70)                                 | 0.313 NE             |
| ESR (≥50 vs. < 50 mm/h)          | 0.55 (0.31–0.99)                 | 0.047                                       | 0.67 (0.27–1.04)                                 | 0.49 (0.25–0.96)     |
| IPS (≥3 vs. <3)                  | 1.08 (1.07–4.04)                 | 0.015                                        | 1.23 (0.63–2.42)                                 | 0.344 NE             |
| VLR risk Score                   |                                  |                                              |                                                  |                     |
| (1 vs. 0)                        | 4.31 (1.00–18.56)                | 0.050                                       | 2.94 (0.67–13.00)                                | 0.155 NA             |
| (2 vs. 0)                        | 7.84 (1.82–33.67)                | 0.006                                       | 6.56 (1.52–28.35)                                | 0.012 NA             |
| (3 vs 0)                         | 15.35 (3.54–66.58)               | <0.001                                       | 11.47 (2.55–51.64)                               | 0.001 NA             |

sHR sub hazard ratio, 95% CI 95% confidence intervals, cHL classical Hodgkin lymphoma, DNE not entered the model, NE not evaluated, NA not applicable, NS nodular sclerosis, MC mixed cellularity, NLPHL nodular lymphocyte-predominant Hodgkin lymphoma, MOPP/MOPP or equivalent regimen, ABVD/ABVD ABVD or equivalent regimen, ESR erythrocyte sedimentation rate, IPS International Prognostic Score, VLR very late relapses, VLR risk score no of risk 4 factors (MC histology, ESR < 50 mm/h, no RT, age ≥ 45 years).

Also evaluated in the model:
<sup>a</sup>Age, gender, stage, treatment with ABVD or equivalents vs. MOPP or equivalents.
<sup>b</sup>Gender, stage.
<sup>c</sup>Gender, stage, leukocytosis.
<sup>d</sup>Fine and Gray model.
Since all estimated HR of the four independent predictors in the final backward multivariate model in ABVDeq-treated subgroup were roughly similar (~2.00 or 0.50), we assigned one point to each unfavorable factor, namely MC, age ≥45 years, ESR < 50 mm/h and omission of RT. The resulting score separated the three cohorts (all patients, ABVDeq-treated and cHL ABVDeq-treated) into four adequate-sized subgroups (0, 1, 2, 3–4 factors) with significantly divergent outcomes (Table 1 and Supplementary Tables 2–4 and Supplementary Fig. 3a–c).

VLRs of HL have been long recognized since 1985 [3] and recorded as late as 30–32 years after diagnosis with 2/3 such cases being NLPHL [14, 15]. Three VLR studies in the 90’s included patients with variable definition (>2, 4 or 5 years), mainly treated with RT alone and/or outdated chemotherapy [4–6]. RT alone was a risk factor for VLR but these results are not applicable in the modern treatment era.

In the era of modern CT ± RT, four small-to-medium sized published studies have roughly included 300–450 patients and reported 16–30 VLRs each, with the most delayed ones recorded at 16.5–22 years [7–10]. Thus they may have not been adequately powered to detect relevant prognostic factors.

In 2017, the GHSG reported a linear VLR risk for 20 years, which was lowest in the advanced-stage trials, suggesting that BEACOPP-based strategies not only reduce PR/ER and LRs but also VLRs, while VLRs were highest in early-stage trials delivering the least intensive approaches, in line with other reports in the 90s [4, 6, 10]. Only demographics, risk classification and trial generation were evaluated and increasing age, male gender and early stages were independent predictors of VLR.

The present study provided novel observations in an attempt to shed light on some of the questions raised above, which remained unanswered even after the large GHSG study. First, we demonstrated that the linear pattern of VLRs continues beyond 20 years up to 25–30 years. Interestingly, we recorded the latest VLR at 35.1 years and recorded 8 cases beyond the 20th year. Second, patients who did not receive RT were more likely to experience VLRs. If this is validated, it may impact the long-term results of recent randomized trials, which are awaited with great interest, because non-inferiority of CT vs. CMT may be affected.

Third, elevated ESR ≥ 50 mm/h was associated with lower VLR risk despite the marginally positive association of its strong correlates (stage and B-symptoms) with VLRs (HR ~1.2–1.5). Elevated ESR denotes biologically active, more aggressive disease, which may have a different biology related to PR/ER but also with some kind of long-term plateau and lower risk of VLR. Thus, some patients with advanced disease, probably those with delayed diagnosis and less inflammatory background reflected by lower ESR, may be more prone to the development of VLR. This hypothesis is supported by the progressively decreasing percentage of ESR ≥ 50 mm/h in patients with PR/ER, LR and VLR (Supplementary Table 1).

Lastly, our most striking finding was that the MC subtype was by far the most likely to be complicated by VLRs in sharp contrast with some kind of long-term plateau and lower risk of VLR. Thus, some patients with advanced disease, probably those with delayed diagnosis and less inflammatory background reflected by lower ESR, may be more prone to the development of VLR. This hypothesis is supported by the progressively decreasing percentage of ESR ≥ 50 mm/h in patients with PR/ER, LR and VLR (Supplementary Table 1).

In conclusion, the present study provides new information by revealing the linear pattern of continuing relapses for up to 25–30 years, describing cases with extremely late relapses up to 35 years, confirming these findings in patients specifically treated with ABVDeq and, most importantly, uncovering previously unrecognized prognostic factors for VLRs, which may not only impact the follow-up strategies and patient counseling but also highlight the unique biology of different histologic subtypes, especially MC. Obviously, this information may be modified with PET-driven strategies and the incorporation of novel agents into the first-line therapy.
10. Pinczes L, Miltenyi Z, Illes A. Young adults diagnosed with Hodgkin lymphoma are at risk of relapsing late: a comprehensive analysis of late relapse in Hodgkin lymphoma. J Cancer Res Clin Oncol. 2018;144:935–43.
11. Viviani S, Mussetti A, Di Bartolo O, Cabras A, Viagussa P, Bonadonna G, et al. Late relapse in Hodgkin lymphoma (HL): a retrospective analysis of patients enrolled on clinical trials at the Istituto Nazionale Tumori of Milan (INT-MI). Blood. 2015;126:2697.
12. Brockelmann PJ, Angelopoulos MK, Vassilakopoulos TP. Prognostic factors in Hodgkin lymphoma. Semin Hematol. 2016;53:155–64.
13. Vassilakopoulos TP, Liaskas A, Rizzuto G, Angelopoulos MK, Giatra H, Kontopidou FN, et al. Very late relapses (VLR) ≥5 years after initial treatment with chemotherapy ± radiotherapy (CT±RT) in Hodgkin lymphoma (HL): a joint study on treatment strategies and prognostic factors for the outcome. 24th Congress of EHA, June 13–16, Amsterdam, Netherlands, HemaSphere Abstract Book. 2019;3:187–8.
14. Lee KM, Spittle MF. Hodgkin’s disease: a case of late relapse. Clin Oncol. 1993;5:399.
15. Shihabi S, Deutsch M, Jacobs SA. Very late relapse of Hodgkin’s disease: a report of five patients. Am J Clin Oncol. 2001;24:576–8.

AUTHOR CONTRIBUTIONS
All authors had substantial contribution to this work. Specific contributions are described as: TPV: designed research, performed research, collected data, analyzed and interpreted data, performed statistical analysis, and wrote the manuscript. EK and FP: analyzed and interpreted data, performed statistical analysis, and contributed to the writing of the manuscript. MKA and AL: performed research, collected data, interpreted data, critically reviewed the manuscript. FNK, XY, MD, MPS, VJA, MA, PD, SS, CC, MB, EK, GB, AK, SK, M-CK, N-AV, EL, GT, and PK: collected data, critically reviewed the manuscript. KK: collected data, interpreted data, critically reviewed the manuscript. GAP: designed research, collected data, interpreted data, critically reviewed the manuscript.

COMPETING INTERESTS
The authors declare no competing interests.

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41408-022-00674-w.

Correspondence and requests for materials should be addressed to Theodoros P. Vassilakopoulos.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022